P=N/A, N=350, Not yet recruiting, Henan Cancer Hospital

Cytotoxic effects on A549 cell lines, compared to sorafenib (4.04 μM) and erlotinib (5.49 μM), showed that compounds 4, 5, 6, 7, 8, 10 and 11 with the IC50 values of 5.50-8.00 μM exhibited very high activities. Molecular docking was carried out for all derivatives to show their binding affinities and orientations inside the active sites of VEGFR-2 and EGFRT790M receptors to support the in vitro results. The data obtained from docking is highly matched with that obtained from biological testing.

P2/3, N=1200, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting

In vivo, SZU305 showed strong antitumor activity without apparent toxicity, particularly when combined with sorafenib or irradiation in a Huh-7 xenograft model. These findings highlight the therapeutic potential of RAD51 degradation as a novel strategy to overcome drug resistance in liver cancer.

This study provides the first comprehensive evaluation of FGFR1-4 expression in ccRCC and suggests that FGFR1 expression may contribute to the immunosuppressive tumor microenvironment by recruiting TAM. These findings indicate that FGFR1 could serve as a potential biomarker for therapeutic strategies and highlight the need for further research to explore FGFR-targeted therapies in ccRCC.

The antifibrotic agents pirfenidone and nintedanib, thought to work primarily through suppression of TGF-β function, are used routinely in clinical practice for non-pancreatic indications, with a first trial in pancreatitis underway. Trials evaluating these licensed therapeutics that include primary diabetes-related endpoints and measures aiming to elucidate the underlying mechanisms of action merit consideration in type 3c diabetes and ultimately in type 2 diabetes and in combinatorial regimens in type 1 diabetes.

The PNI score is a promising biomarker for predicting survival in HCC patients receiving TACE combined with lenvatinib, with or without PD-1 inhibitors. Low PNI is associated with poor survival outcomes, highlighting its potential utility in risk stratification and treatment planning.

Clinically approved drugs such as Dasatinib (targeting CSK) and Crizotinib (targeting MET) emerged as promising candidates due to favorable pharmacokinetics and known bioactivity. Host-directed therapeutics could offer alternative strategies to conventional antibiotic therapy, addressing challenges such as resistance and infection recurrence, providing a foundation for future experimental validation and development of host-targeted interventions for infection control.

P4, N=279, Completed, Hospices Civils de Lyon | Recruiting --> Completed

P1, N=30, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026

P2, N=39, Recruiting, The First Affiliated Hospital with Nanjing Medical University